Home / Drug discovery / Biology / Bioinformatics
Bioinformatics for drug discovery and development
Our bioinformatics drug discovery services turn complex biological data into clear, actionable insight. Working across discovery and development, we combine computational analysis with experimental biology to guide decisions on biomarkers, patient selection, and mechanisms of action.
The result: faster interpretation, stronger predictions and more confident progress from early studies to IND.
Integrated biology CRO capabilities in bioinformatics
Our bioinformatics group works hand in hand with our wet-lab biologists to turn raw experimental results into meaning you can act on. With access to more than 270 annotated cell lines, we connect drug response data directly to genetic profiles to reveal the mechanisms and biomarkers that matter most.
Beyond single studies, we integrate synergy analysis, mechanistic biology and high-throughput screening data into cohesive datasets that support decision-making and regulatory submission.
The result is a clear, evidence-driven view of compound behavior that moves your discovery project forward.
Related services
Our bioinformatics knowledge
270+ cancer cell lines
Comprehensive profiling supports biomarker discovery, patient stratification and mechanism-of-action studies.
Custom algorithms and analytics
Proprietary bioinformatics tools for synergy analysis, cell panel profiling, and mechanistic studies.
Phase-appropriate reporting
Data analysis aligned with preclinical and translational development requirements.
Biology integrated with computation
Bioinformatics sits at the core of our biology services, connecting experiment and analysis within the same environment. By interpreting data where it’s generated, we shorten turnaround times and eliminate disconnects between lab and computation. The result is faster insight, data continuity and confident decisions.
What do our partners say?
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
Your discovery and development partner
Our expert teams in Europe and the US, provide biology services integrated with medicinal, computational, synthetic and specialty chemistry, ADME-tox, and development-scale CMC programs, ensuring continuity across drug discovery and early development.
We share data transparently, adapt quickly if the unexpected occurs, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous.
Resources we think you'll love
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Whitepaper
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Whitepaper
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our bioassay drug discovery experts
See how we can support the discovery and development of your next breakthrough.